We aim to maximize the potential of the small-molecule compounds we have previously obtained. To achieve this goal, we invite proposals addressing the discovery of new target diseases or conditions for these compounds.
Pharmaceuticals Research Center
Laboratory for Medicinal Chemistry
Creating for Tomorrow
“ Identification of Novel Drug Indications ”
Message
-
Yasuhiro Wada, PhD
Principal Scientist
Laboratory for Medicinal Chemistry
Recruitment theme
- 8.1 Discovery of new indications for secreted frizzled-related protein 1 (sFRP1) inhibitors
-
- Chemical compounds developed at Asahi Kasei Pharma will be provided at no cost. (Their structural information will not be disclosed.)
- The characteristics of our compounds:
- a )
- Have approximately 50-fold higher sFRP1-inhibition activities, as compared with the commercially-available tool compound, WAY-316606.
- b )
- Can be administered orally.
- High priority will be given to research projects that focus on the field of orthopedics, the medical field where Asahi Kasei Pharma directs its research and development efforts. (Proposals involving osteoporosis research will not be considered.)
- 8.2 Discovery of new indications for transient receptor potential ankyrin 1 (TRPA1) inhibitors in the field of orthopedics
-
- A chemical compound developed at Asahi Kasei Pharma will be provided at no cost. (Its structural information will not be disclosed.)
- The characteristics of our compound:
- a )
- Can inhibit both human and rat TRPA1 with an IC50 value at a few nanomolar.
- b )
- Can be administered orally.
- Target indications should belong to the group of orthopedic disorders.
(Proposals involving pain will not be considered.)
Subscription
Click “Apply” to proceed to the application form.
